Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Maze Therapeutics, Inc.NASDAQ: MAZE

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 53.9M shares rose 23.1% year over year, ahead of the +6.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 25.4% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.1% holds above the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
53.9M+25.4% QoQ
Last fiscal yearDec 2025
42.98M-1.9% YoY
LTMMar 2026
46.63M+6.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.1%——
1 year-1.9%——
3-year CAGR-0.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
42.98M USD
Year-over-year change
-1.9%
3-year CAGR
-0.6%

Weighted Avg Shares vs competitors

How MAZE compares with its peers on the latest reported figures

  • MAZE's LTM Mar 2026 weighted avg shares of 46.63M shares is the 6th highest of the 8 companies compared; the peer median is 81.93M shares.
  • Its year-over-year change of +6.5% is the 5th highest of 8, against a peer median of +7.3%.
  • Over three fiscal years its annual growth of -0.6% compares with a peer median of +13.4%.
MAZE Competitors Peer median
Weighted Avg Shares for MAZE and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026242.83M +2.6%+15.0%
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +5.9%+11.8%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.8%—
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
Peer median (excluding MAZE) 81.93M+7.3%+13.4%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.